Equal Access to Treatment Erases Difference in Outcomes Between White and African American Patients...
If African American patients with multiple myeloma (MM) are given equal access to treatments, they have outcomes that are as good as or better...
Evaluating Safety and Efficacy of Venetoclax Plus R-CHOP in Non-Hodgkin Lymphoma
According to results from the phase Ib CAVALLI study, treatment with the oral BCL2 inhibitor venetoclax, combined with standard immunochemotherapy, induced high response rates...
Study Finds Urgent Need for Sickle Cell Disease Screening Among African Refugees in Italy
Most refugees who arrive at the Mediterranean coast of Italy and other southern European countries are leaving areas where sickle cell disease (SCD) is...
Walking Speed Predicts Frailty, Survival, and Other Outcomes in Older Patients With Blood Cancers
Walking speed was a reliable indicator of frailty among older patients with blood cancers, and this frailty measure was a more accurate predictor of...
Post-Transplant Pembrolizumab Consolidation Improves PFS in Relapsed/Refractory Hodgkin Lymphoma
In patients with high-risk, relapsed/refractory classical Hodgkin lymphoma (cHL) who have undergone autologous hematopoietic cell transplantation (AHCT), consolidation therapy with the PD-1 inhibitor pembrolizumab...
New Study Supports “R2” Regimen in Previously Untreated Follicular Lymphoma
The combination of lenalidomide and rituximab, known as the R2 regimen, improved progression-free survival (PFS), time to next treatment (TTNT), and complete response (CR)...
Higher Dose, Longer Duration of Eltrombopag Improves Likelihood of Response in Refractory Severe Aplastic...
The thrombopoietin receptor agonist eltrombopag was approved by the U.S. Food and Drug Administration for the treatment of adults with refractory severe aplastic anemia...
Is “Watching and Waiting” Enough for Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma?
For patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), active surveillance appeared to be a feasible initial management strategy, according to an analysis published in...
Evaluating Thalidomide-Cyclophosphamide-Prednisone for Idiopathic Multicentric Castleman Disease
An oral combination of thalidomide, cyclophosphamide, and prednisone (TCP) induced durable tumor and symptomatic response rates in nearly half of patients with newly diagnosed...
Venetoclax Plus Obinutuzumab Confers High MRD-Negative Rates in CLL
Results from a phase Ib study demonstrated that the combination of the BCL2 inhibitor venetoclax with the anti-CD20 monoclonal antibody obinutuzumab was safe and...
Current Issue
July 2019 Bonus Mid-Year Edition, Volume 5, Issue 9
This issue features a look at research espionage, coverage from the ASCO and EHA annual meetings, and more.
